Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company developing novel serotonergic agonists (NSAs), announced it will host an investor presentation on Oct. 21, 2026, at 9 a.m. EDT. The event will highlight HLP003, the company’s proprietary NSA in Phase 3 development for the adjunctive treatment of major depressive disorder, and HLP004, its proprietary NSA in Phase 2 development for generalized anxiety disorder. The presentation will also feature perspectives from key opinion leaders on the evolving depression and anxiety treatment landscape, followed by a question-and-answer session with Helus Pharma executives. The live webcast will be accessible through the company’s website, with a replay available following the presentation. To view the full press release, visit https://ibn.fm/akaNj.
Helus Pharma(TM), the commercial operating name of Cybin Inc., founded in 2019, is committed to helping minds heal by developing proprietary NSAs—synthetic molecules designed to activate serotonin pathways believed to promote neuroplasticity. The company’s NSAs aim to address the large unmet need for people suffering from depression, anxiety, and other mental health conditions. HLP003 has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration for the adjunctive treatment of major depressive disorder, underscoring its potential to offer durable improvements in mental health. With class-leading data, Helus Pharma aims to improve the treatment landscape through the introduction of NSAs. The company operates in Canada, the United States, the United Kingdom and Ireland. For more information, visit www.helus.com.
The investor presentation matters because it provides a window into two late-stage programs targeting conditions that affect millions worldwide. Major depressive disorder and generalized anxiety disorder are leading causes of disability, and existing treatments often fail to provide adequate relief. Helus Pharma’s NSAs represent a novel mechanism that could offer new hope for patients who have not responded to conventional therapies. The inclusion of key opinion leaders suggests the company is seeking to build clinical credibility and educate investors about the science behind its approach. For the industry, this event signals continued momentum in the development of psychedelic-inspired medicines, a space that has attracted significant investment and regulatory interest. If HLP003 and HLP004 succeed, they could reshape treatment paradigms and create new market opportunities. For readers, this news highlights the importance of staying informed about emerging mental health therapies and the companies driving innovation.
BioMedWire (“BMW”) is a specialized communications platform focused on the latest developments in the Biotechnology, Biomedical Sciences, and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution, and tailored corporate communications solutions. For more information, visit BioMedWire or see the full disclaimer at https://www.BioMedWire.com/Disclaimer.
